Biotech

FogPharma’s has reached early clinical development with therapeutic candidate that takes a novel approach to treatment solid tumors. The company...

Newly public biotech Kyverna Therapeutics could be a blockbuster cell therapy developer for autoimmune disease, according to Morgan Stanley. Analyst...

Verify Your Email Address Your account contact email hasn’t been verified yet. Please verify your email address Go to Edit...

A new University of California – Riverside (UCR) study found that introducing a simple, renewable chemical to the pretreatment step...

“Science doesn’t care what markets are doing, and science moves forward”… These bold words are from Robert Nelsen, co-founder and...

I’ve been clocking Nvidia’s success since the beginning of 2023. It’s a microchip maker that has been able to grow...

Arcellx, a biotechnology company, has promoted its vice president of investor relations to chief investor and communications officer. The biotech...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in...

Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching a late stage of financing...

Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners, one of the drug industry’s...

Gilead won’t ac­quire check­point on­col­o­gy biotech Tizona Gilead has now passed on two biotech buy­out op­tions that it forged in...

Encouraging farmers to use biotech and other climate tech to make agriculture more sustainable requires ensuring that their impact on...